Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical company Futura Medical reported narrower losses as research and development spend fell sharply.
For the year ended 31 December 2020, pre-tax losses narrowed to £2.9 million from £11.1 million.
Research and development costs fell to £1.9 million from £10.0 million.
'The company is well positioned to deliver further positive news through 2021 especially around commercialisation of MED3000 and our objective to deliver a long term and sustainable revenue for shareholders,' the company said.
At 10:10am: (LON:FUM) Futura Medical PLC share price was 0p at 14.75p